Trial Profile
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Mar 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Cerebral palsy; Muscle spasticity
- Focus Registrational; Therapeutic Use
- Acronyms XARA
- Sponsors Merz Pharmaceuticals GmbH
- 22 Sep 2021 Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
- 22 Sep 2021 Results of pooled analysis of two randomized Phase 3 studies, TIM (NCT01893411) and XARA (NCT02002884) assessing efficacy and safety of incobotulinumtoxinA for lower-limb (LL) and upper-limb (UL) spasticity in children and adolescents with cerebral palsy, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
- 22 Sep 2021 Results assessing effect of incobotulinumtoxinA on spasticity-related pain (SRP) using pooled data from three large Phase 3 pediatric studies (TIM (NCT01893411); TIMO (NCT01905683) & XARA (NCT02002884)) presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.